New pill targets genetic weak spot in aggressive tumors
NCT ID NCT06710847
First seen Feb 02, 2026 · Last updated May 09, 2026 · Updated 13 times
Summary
This study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic features (dMMR or MSI-H). The drug aims to shrink tumors by blocking a DNA repair protein. The trial will check safety, side effects, and how well the drug works alone or with another cancer medicine.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Los Angeles, California, 90095, United States
-
GSK Investigational Site
Denver, Colorado, 80218, United States
-
GSK Investigational Site
Detroit, Michigan, 48201, United States
-
GSK Investigational Site
New York, New York, 10016, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19104, United States
-
GSK Investigational Site
Philadelphia, Pennsylvania, 19107, United States
-
GSK Investigational Site
Melbourne, Victoria, 3000, Australia
-
GSK Investigational Site
Brussels, 1200, Belgium
-
GSK Investigational Site
Ghent, 9000, Belgium
-
GSK Investigational Site
Leuven, 3000, Belgium
-
GSK Investigational Site
Chiba, 277-8577, Japan
-
GSK Investigational Site
Shizuoka, 411-8777, Japan
-
GSK Investigational Site
Tokyo, 104-0045, Japan
-
GSK Investigational Site
Tokyo, 135-8550, Japan
-
GSK Investigational Site
Amsterdam, 1066 CX, Netherlands
-
GSK Investigational Site
Daegu, 41404, South Korea
-
GSK Investigational Site
Gyeonggi-do, 10408, South Korea
-
GSK Investigational Site
Seoul, 03080, South Korea
-
GSK Investigational Site
Barcelona, 08023, Spain
-
GSK Investigational Site
Barcelona, 08035, Spain
-
GSK Investigational Site
Madrid, 28040, Spain
-
GSK Investigational Site
Málaga, 29010, Spain
Conditions
Explore the condition pages connected to this study.